These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 32685378)

  • 41. The origin of halitosis in cystinotic patients due to cysteamine treatment.
    Besouw M; Blom H; Tangerman A; de Graaf-Hess A; Levtchenko E
    Mol Genet Metab; 2007 Jul; 91(3):228-33. PubMed ID: 17513151
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The treatment of cystinosis with cysteamine and phosphocysteamine in the United Kingdom and Eire.
    van't Hoff WG; Gretz N
    Pediatr Nephrol; 1995 Dec; 9(6):685-9. PubMed ID: 8747105
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Synergistic Cysteamine Delivery Nanowafer as an Efficacious Treatment Modality for Corneal Cystinosis.
    Marcano DC; Shin CS; Lee B; Isenhart LC; Liu X; Li F; Jester JV; Pflugfelder SC; Simpson J; Acharya G
    Mol Pharm; 2016 Oct; 13(10):3468-3477. PubMed ID: 27571217
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Halitosis in cystinosis patients after administration of immediate-release cysteamine bitartrate compared to delayed-release cysteamine bitartrate.
    Besouw M; Tangerman A; Cornelissen E; Rioux P; Levtchenko E
    Mol Genet Metab; 2012 Sep; 107(1-2):234-6. PubMed ID: 22832073
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Pantethine and cystamine deplete cystine from cystinotic fibroblasts via efflux of cysteamine-cysteine mixed disulfide.
    Butler JD; Zatz M
    J Clin Invest; 1984 Aug; 74(2):411-6. PubMed ID: 6746900
    [TBL] [Abstract][Full Text] [Related]  

  • 46. An international cohort study spanning five decades assessed outcomes of nephropathic cystinosis.
    Emma F; Hoff WV; Hohenfellner K; Topaloglu R; Greco M; Ariceta G; Bettini C; Bockenhauer D; Veys K; Pape L; Hulton S; Collin S; Ozaltin F; Servais A; Deschênes G; Novo R; Bertholet-Thomas A; Oh J; Cornelissen E; Janssen M; Haffner D; Ravà L; Antignac C; Devuyst O; Niaudet P; Levtchenko E
    Kidney Int; 2021 Nov; 100(5):1112-1123. PubMed ID: 34237326
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Cystinosis : Diagnosis, cystine-depleting therapy, and transition].
    Kaufeld J; Weber LT; Kurschat C; Canaan-Kuehl S; Brand E; Oh J; Pape L
    Internist (Berl); 2018 Aug; 59(8):861-867. PubMed ID: 29671012
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cysteamine prevents inhibition of thiol-containing enzymes caused by cystine or cystine dimethylester loading in rat brain cortex.
    Rech VC; Feksa LR; Fleck RM; Athaydes GA; Dornelles PK; Rodrigues-Junior V; Wannmacher CM
    Metab Brain Dis; 2008 Jun; 23(2):133-45. PubMed ID: 18418703
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Corneal crystals in nephropathic cystinosis: natural history and treatment with cysteamine eyedrops.
    Gahl WA; Kuehl EM; Iwata F; Lindblad A; Kaiser-Kupfer MI
    Mol Genet Metab; 2000; 71(1-2):100-20. PubMed ID: 11001803
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Pharmacological treatment of nephropathic cystinosis with cysteamine.
    Kleta R; Gahl WA
    Expert Opin Pharmacother; 2004 Nov; 5(11):2255-62. PubMed ID: 15500372
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Clinical utility of chitotriosidase enzyme activity in nephropathic cystinosis.
    Elmonem MA; Makar SH; van den Heuvel L; Abdelaziz H; Abdelrahman SM; Bossuyt X; Janssen MC; Cornelissen EA; Lefeber DJ; Joosten LA; Nabhan MM; Arcolino FO; Hassan FA; Gaide Chevronnay HP; Soliman NA; Levtchenko E
    Orphanet J Rare Dis; 2014 Nov; 9():155. PubMed ID: 25407738
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Cystine depletion by WR-1065 in cystinotic cells. Mechanism of action.
    Butler JD; Gahl WA; Tietze F
    Biochem Pharmacol; 1985 Jun; 34(12):2179-85. PubMed ID: 2988568
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Cysteamine prevents and reverses the inhibition of pyruvate kinase activity caused by cystine in rat heart.
    Rosa TG; de Souza Wyse AT; Wajner M; Wannmacher CM
    Biochim Biophys Acta; 2004 Jun; 1689(2):114-9. PubMed ID: 15196592
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cysteamine (Cystagon®) adherence in patients with cystinosis in Spain: successful in children and a challenge in adolescents and adults.
    Ariceta G; Lara E; Camacho JA; Oppenheimer F; Vara J; Santos F; Muñoz MA; Cantarell C; Gil Calvo M; Romero R; Valenciano B; García-Nieto V; Sanahuja MJ; Crespo J; Justa ML; Urisarri A; Bedoya R; Bueno A; Daza A; Bravo J; Llamas F; Jiménez Del Cerro LA
    Nephrol Dial Transplant; 2015 Mar; 30(3):475-80. PubMed ID: 25348508
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Negligible urinary cysteamine loss in cystinosis patients with Fanconi syndrome.
    Levtchenko EN; de Graaf-Hess A; Blom HJ; Monnens LA
    Clin Nephrol; 2002 May; 57(5):349-51. PubMed ID: 12036193
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Cystinosis. Intracellular cystine depletion by aminothiols in vitro and in vivo.
    Thoene JG; Oshima RG; Crawhall JC; Olson DL; Schneider JA
    J Clin Invest; 1976 Jul; 58(1):180-9. PubMed ID: 932205
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Adherence to cysteamine in nephropathic cystinosis: A unique electronic monitoring experience for a better understanding. A prospective cohort study: CrYSTobs.
    Gaillard S; Roche L; Lemoine S; Deschênes G; Morin D; Vianey-Saban C; Acquaviva-Bourdain C; Ranchin B; Bacchetta J; Kassai B; Nony P; Bodénan E; Laudy V; Rouges C; Zarrabian S; Subtil F; Mercier C; Cochat P; Bertholet-Thomas A
    Pediatr Nephrol; 2021 Mar; 36(3):581-589. PubMed ID: 32901297
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cysteamine therapy for children with nephropathic cystinosis.
    Gahl WA; Reed GF; Thoene JG; Schulman JD; Rizzo WB; Jonas AJ; Denman DW; Schlesselman JJ; Corden BJ; Schneider JA
    N Engl J Med; 1987 Apr; 316(16):971-7. PubMed ID: 3550461
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Cystinosis: clinical presentation, pathogenesis and treatment.
    Ivanova E; De Leo MG; De Matteis MA; Levtchenko E
    Pediatr Endocrinol Rev; 2014 Sep; 12 Suppl 1():176-84. PubMed ID: 25345100
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Nephropathic Cystinosis: Symptoms, Treatment, and Perspectives of a Systemic Disease.
    Bäumner S; Weber LT
    Front Pediatr; 2018; 6():58. PubMed ID: 29594088
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.